By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Clinical Research. According to news reporting originating from Bristol, United Kingdom, by NewsRx correspondents, research stated, "Restenosis, the re-narrowing of a blood vessel after removal of atherosclerotic plaque, is a major limitation of surgical treatments for atherosclerosis. Various attempts to prevent or treat restenosis by pharmacological or mechanical approaches have had limited success in clinical trials."
Our news editors obtained a quote from the research from the University of Bristol, "Hence, there is wide interest in developing new strategies to prevent or treat restenosis. This review discusses 'a new-generation therapy' that uses functional nanoparticles to effectively deliver active drug molecules. The potential platforms for nanoparticle-based solutions to restenosis include organic (e.g. polymers, liposomes, and proteins) and inorganic nanoparticles (e.g. layered double hydroxides, titanium oxide nanotubes, and magnetic nanoparticles,). Many in vitro and in vivo studies based on these platforms demonstrate the feasibility and potential of using nanoparticle drug delivery systems for preventing or treating restenosis, but as yet few have reached clinical trials."
According to the news editors, the research concluded: "It is suggested that using inorganic nanoparticles to target deliver multi-functional drugs will be a promising approach to preventing or treating restenosis."
For more information on this research see: Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems. Current Pharmaceutical Design, 2013;19(35):6330-6339. Current Pharmaceutical Design can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates. (Bentham Science Publishers - www.benthamscience.com; Current Pharmaceutical Design - www.benthamscience.com/cpd/index.htm)
The news editors report that additional information may be obtained by contacting Z. Gua, University of Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, United Kingdom. Additional authors for this research include B.E. Rolfe, A.C. Thomas and Z.P. Xu (see also Clinical Research).
Keywords for this news article include: Europe, Bristol, Surgery, Therapy, Cardiology, Restenosis, Nanoparticle, Heart Disease, United Kingdom, Cardiovascular, Nanotechnology, Clinical Research, Surgical Technology, Drug Delivery Systems, Emerging Technologies, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC